Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | F3 | P13726 | 4/20 | 0.36 |
| ▸ | DRD1 | P21728 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028542 | 0.90 | KDM4E (0.38) | KDM4EMEN1MAPTKMT2ANPC1 | |
| SCHEMBL16564103 | 0.83 | KDM4E (0.54) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL16066091 | 0.79 | KDM4E (0.47) | KDM4EMAPTKMT2AALDH1A1LMNA | |
| SCHEMBL10001964 | 0.78 | AR (0.42) | KDM4EMAPTALDH1A1LMNAMGAM | |
| SCHEMBL30028054 | 0.76 | MAOB (0.43) | MAPTSMN1; SMN2 | |
| SCHEMBL16564053 | 0.76 | KDM4E (0.40) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL12904364 | 0.76 | KDM4E (0.43) | KDM4EMEN1MAPTKMT2ANPC1 | |
| SCHEMBL16564368 | 0.74 | KDM4E (0.39) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL2742557 | 0.72 | AGTR2 (0.45) | KDM4ELMNA | |
| SCHEMBL15902735 | 0.71 | KDM4E (0.69) | KDM4EMEN1MAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| CN-115260185-A | Deuterated derivatives of corydaline and stepholidine and preparation method thereof | 杨征 | 2022-11-01 | — | — | CN | disclosed |
| EP-2848617-B1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-01-12 | — | — | EP | disclosed |
| WO-2021067490-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2021-04-08 | — | — | WO | disclosed |
| US-9751882-B2 | Diaryl[A, G]quinolizidine compound, preparation method therefor, pharmaceutical composition, and uses thereof | KINGSOUND & PARTNER (CN) | 2017-09-05 | — | — | US | disclosed |
| US-20150141419-A1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-21 | — | — | US | disclosed |
| EP-2848617-A1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-03-18 | — | — | EP | disclosed |
| US-8815900-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-08-26 | — | — | US | disclosed |
| US-8815900-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-08-26 | — | — | US | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-20110269754-A1 | COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2011-11-03 | — | — | US | disclosed |
| US-8003795-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2011-08-23 | — | — | US | disclosed |
| US-8003795-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2011-08-23 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
| WO-2011006000-A1 | BERBERINE DERIVATIVES USEFUL FOR MODULATING LIPID LEVELS AND THEIR METHODS OF SYNTHESIS | LIU HAIYAN (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010075469-A1 | CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2010-07-01 | — | — | WO | disclosed |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2009-02-19 | — | — | US | disclosed |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002873-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | LIPC, LDLR, PCSK9 | KDM4E 3820/4885MEN1 3178/4885MAPT 3477/4885 |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | KDM4E 2429/4885MEN1 4500/4885MAPT 2669/4885 |
| US-20150141419-A1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | HTR5A, HTR1F, QDPR | KDM4E 4401/4885MEN1 2484/4885MAPT 2859/4885 |
| US-20110269754-A1 | COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS | LIPC, LIPE, BCHE | KDM4E 3052/4885MEN1 3385/4885MAPT 1368/4885 |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, BCHE, LIPE | KDM4E 3114/4885MEN1 3254/4885MAPT 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.